clinical-trials
47 stories tagged "clinical-trials"
A Daily Fiber Powder Eased Knee Arthritis Pain, and People's Grip Got Stronger Too
Six weeks of inulin, a prebiotic sold by the tub, cut knee pain 1.11 points more than placebo and added 4.62 kilograms of grip strength in a Nottingham trial, while the gut hormone GLP-1 rose alongside.
CancerNorway's Own Screening Adviser Ran the Numbers: About One in 86 Screened Women Overdiagnosed
By its own adviser's estimate, Norway's mammography program overdiagnoses about one in 86 screened women, roughly three for every breast cancer death it prevents, while a 58-trial review finds early detection is no reliable stand-in for fewer deaths.
CancerRoche's KRAS Pill Beat the Older Drugs on Survival, an Endpoint Lumakras Never Won Against Chemotherapy
Median survival ran 17.7 months on divarasib and 12.0 on a control arm that was nine-tenths Lumakras, a drug whose own confirmatory trial showed no survival edge over chemotherapy.
Drugs & FDAThe PTSD Magnet Therapy Touting 68 Percent Remission Hasn't Shown Its Placebo Arm
In Wave Neuroscience's earlier sham-controlled trial, veterans on a coil built to deliver no magnetic field improved about two-thirds as much as those on active stimulation. The sham results from the trial behind its FDA clearance still haven't been posted.
Brain & AgingThe Omega-3 Trial Headlined as a Brain-Health Bust Was Built to Measure Spinal Fluid
Two years of high-dose DHA reached the spinal fluid of older adults exactly as planned. The memory scores behind the "no benefit" headlines were an exploratory outcome, and 38 percent of volunteers dropped out.
CancerCompass Plans to File a Biliary Cancer Drug Without the Survival Trial the FDA Asked For
Tovecimig plus chemotherapy shrank more biliary tract tumors than chemotherapy alone, but median survival was 8.9 months against 9.4, and 93.5 percent of the combination arm had grade 3 or worse adverse events. The FDA recommended a survival trial before filing. Compass plans to file anyway.
Drugs & FDABlood Pressure Fell Further on the Switched-Off Ear Clip Than on the Real Device
Daytime systolic pressure fell 5.50 points on a zero-current fake ear clip and 3.15 on the active device. Queen Mary's headline said the stimulation "shows potential."
CancerHengrui's Breast Cancer Drug More Than Doubled Progression-Free Survival While Severe Anemia Hit Four in Ten Patients
Trastuzumab rezetecan pushed median progression-free survival to 16.4 months from 6.8 on chemotherapy in 551 patients, all treated in China, while grade 3 or worse anemia reached 42.8 percent against 4.8 percent.
Drugs & FDASix Months Against Twelve: How Essilor's New Myopia Lens Got Called 'Twice as Fast'
Stellest 2.0's six-month numbers sat close to the original lens's one-year result from a separate trial, and a company symposium in London called that twice as fast. The children's lens is on sale abroad and has not been cleared by the FDA.
Brain & AgingPsilocybin Trial's Banked Blood Shows Parkinson's Inflammation Markers Still Lower a Month Later
Five inflammatory signals were still below baseline a month after the second psilocybin session, in blood banked from nine Parkinson's patients in an uncontrolled UCSF pilot whose investigators carry psychedelic-industry ties.
CancerThe Vitamin C Trial That Missed Its Goal and Counted 11 Deaths Against 24
Copenhagen and USC researchers gave 1,000 mg of plain vitamin C a day to people with pre-leukemic blood disorders. The mutant clones grew regardless, but over three years of follow-up 11 patients assigned to the vitamin died, against 24 assigned to placebo.
Drugs & FDAGSK's Hepatitis B Drug Got a Label That Reaches Patients It Functionally Cured About One Time in 14
Below 1,000 IU/mL of surface antigen, 26 percent of treated patients reached functional cure. Between 1,000 and 3,000, a range the FDA's label also covers, GSK's own counts work out to about 7 percent, for a weekly injection boxed for serious liver reactions and low platelets.
CancerThe Glioblastoma Trial No Drug Company Paid For Posted an 82% Six-Month Progression-Free Rate
Calgary oncologists bought controlled-release niacin at retail, added it to standard treatment, and cleared their own preset bar with room to spare. The trial is small, single-arm and untidy on paper, and it was paid for entirely with grant money.
CancerNature Medicine Retracted the Lung Cancer Trial That Made Infusion Timing Look Like a Free Win
Its protocol was dated January 2022 but cited papers from 2024, and the editors called its survival curve smoother than a phase 3 trial should produce. A top journal published it anyway. The early-infusion claim is gone, but the body-clock question is still open.
CancerKetamine Failed Its Only Adequately Powered Cancer-Pain Trial, and Palliative Care Still Reaches for It
Ketamine's one adequately powered trial in advanced cancer pain found no benefit over placebo, more toxicity and worse quality of life. Fourteen years on, a 2026 review still tells clinicians to consider it.
Autoimmune & InflammationNovartis Halted Eight Autoimmune CAR-T Trials After Three Deaths, Then Called the Killer a "Known Risk"
Three people in Novartis's rap-cel trials died after a runaway inflammatory syndrome, and Bristol Myers froze enrollment in its rival product. Faster manufacturing is the leading suspect, and no public report yet says how many patients got the drug.
CancerMerck and Moderna Say Their Melanoma Vaccine Worked, but Two Months On the Public Still Hasn't Seen by How Much
Merck and Moderna have announced only that their phase 3 met its endpoints. The smaller trial behind the excitement missed the conventional two-sided significance bar, and one bank has modeled a price as high as $475,000 per patient.
Drugs & FDAGenSight's Blindness Gene Therapy Reached the NEJM on the Same Day It Reported €0.7 Million in Cash
Seven of ten patients blinded by retinitis pigmentosa sensed more light through special goggles after one gene injection, in an uncontrolled trial whose sponsor held €0.7 million on September 30 and warned it may not survive the year.
Autoimmune & InflammationKnee Pain Fell From 7 to 3 After This Artery Procedure, but It Keeps Struggling to Beat a Fake One
Berlin doctors plugged inflamed knee vessels with gelatin beads built to dissolve within hours, and median pain fell from 7 to 3 over a year. Nobody got a sham, and the Rotterdam trial that used one calls the effect mainly placebo.
Drugs & FDAA Heart-Failure Implant Won by 40 Points on a Questionnaire Filled Out by Patients Who Knew Which Arm They Were In
Patients given Berlin Heals' microcurrent implant reported quality-of-life gains eight times the control arm's in an open-label trial. The blood marker and exercise test that could have backed them up showed no significant difference, and the company paid for the study.
Metabolic & WeightThe 'Self-Destruct' Fat Shot Billed as Obesity Medicine Faces Its Pivotal Trial Below the Obesity Line
Caliway's CBL-514 shrank belly fat in small trials and drew obesity headlines at EASD, but its phase 3 caps enrollment below a BMI of 30 and grades flatter stomachs, not weight.
Drugs & FDATerence Tao Fears a Cancer Cure Nobody Can Explain. The FDA Clears Cancer Drugs That Never Proved They Extend Life.
Terence Tao says he would want a human expert to understand an AI cancer cure before taking it. The oncologist Vinay Prasad says that misses how medicine already works, and the receipts show the cancer drugs worth fearing are the legible ones approved on a shrinking tumor that never proved they help
InvestigationsIn Pfizer's Pivotal Trial, a Volunteer's Pericarditis Became a 'Suspected COVID' Case That Counted Against No One
The only Argentine site in Pfizer's pivotal trial was run by the same doctor who authored the results, and when a 35-year-old developed pericarditis after his second dose, the records moved the episode off the vaccine's ledger.
Drugs & FDAGaming a Cancer Trial Is 'Cheap and Easy,' Says a Former Top FDA Official
Vinay Prasad says nobody needs AI to fake a phase 3 cancer win, and a Mayo Clinic audit found 16 of 96 FDA cancer approvals rested on control arms its authors judged suboptimal.